Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Mar. 13, 2026 at 7:52am

Got story updates? Submit your updates here. ›

In a meta-analysis of 23 studies, patients with head and neck cancer had a far higher pathologic response rate when they received chemoimmunotherapy before surgery vs immunotherapy alone. Randomized clinical trial evidence on additional outcomes is still needed.

Why it matters

Neoadjuvant immunotherapy is an established standard of care prior to surgery in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC), but questions remain about the efficacy of neoadjuvant immunotherapy alone compared with neoadjuvant chemoimmunotherapy.

The details

Researchers conducted a systematic review of 23 prospective phase 1 and 2 trials involving 751 patients with treatment-naive, resectable HNSCC. Prior to surgery, 357 patients received chemoimmunotherapy, 102 received dual-agent immunotherapy, and 292 received single-agent immunotherapy. The meta-analysis found pooled rates of major and complete pathologic response were 66% for chemoimmunotherapy, 18% for dual-agent immunotherapy, and 6% for single-agent immunotherapy.

  • The study was published online on March 12, 2026 in JAMA Otolaryngology-Head & Neck Surgery.

The players

Linda X. Yin

The lead author of the study, from the Mayo Clinic in Rochester, Minnesota.

Kevin Contrera

A physician at the University of Pittsburgh Medical Center who wrote an accompanying editorial.

Got photos? Submit your photos here. ›

What they’re saying

“Evidence from this pooled meta-analysis reporting differential pathologic response rates to neoadjuvant chemoimmunotherapy compared with immunotherapy alone calls for randomized phase 3 trials directly comparing the 2 regimens in HNSCC.”

— Linda X. Yin (JAMA Otolaryngology-Head & Neck Surgery)

“Only through such rigorously designed studies can the incremental value (and appropriate patient population) for neoadjuvant chemoimmunotherapy in curative-intent HNSCC be clearly defined.”

— Kevin Contrera, Physician, University of Pittsburgh Medical Center (JAMA Otolaryngology-Head & Neck Surgery)

What’s next

Randomized clinical trials directly comparing neoadjuvant chemoimmunotherapy and immunotherapy alone are needed to determine the impact on patient survival.

The takeaway

This meta-analysis suggests that neoadjuvant chemoimmunotherapy may be more effective than immunotherapy alone in achieving pathologic response in head and neck cancer patients, but further research is required to understand the full implications for patient outcomes.